V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008773 | 240005358 | 1.68 | 48 | Palliative (P) | 2016-12-04 | 2016-12-20 | Triple Intrathecal | N | N | 240022635 | OXALIPLATIN + MDG |
| 240008774 | 240005359 | 0 | 87 | Palliative (P) | 2013-12-16 | 2013-12-22 | CARBOPLATIN + RT | N | N | 240022659 | FLAG + IDARUBICIN |
| 240008775 | 240010945 | 1.51 | 57.5 | Curative (C) | 2018-01-07 | 2018-01-13 | FCR Oral - Cycle 2 onwards | 02 | N | 240022674 | R-EPOCH |
| 240008776 | 240005360 | 1.8 | 102.5 | Palliative (P) | 2018-05-08 | 2018-05-08 | Carboplatin + Vinorelbine Oral | N | N | 240022676 | CLADRIBINE |
| 240008777 | 240010946 | 1.63 | 73 | Curative (C) | 2015-11-09 | 2015-11-09 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | null | N | 240022748 | FCR |
| 240008778 | 240010946 | 1.69 | 58.8 | Curative (C) | 2014-08-18 | 2014-08-22 | CISPLATIN + FLUOROURACIL + RT | N | N | 240022748 | CISPLATIN + ETOPOSIDE |
| 240008779 | 240010946 | 1.55 | 63.2 | Palliative (P) | 2014-12-01 | 2014-12-03 | Methotrexate intrathecal | N | N | 240022748 | BRENTUXIMAB |
| 240008780 | 240010946 | null | 77.5 | Palliative (P) | 2014-04-20 | 2014-05-20 | TCH (21 day Trastuzumab) Maint | null | N | 240022748 | FCR |
| 240008781 | 240005361 | 1.73 | 68 | Palliative (P) | 2015-01-31 | 2015-02-13 | Gemcitabine + Oxaliplatin | 02 | N | 240022810 | INCA TRIAL |
| 240008782 | 240005361 | 1.82 | 55 | Palliative (P) | 2017-07-14 | 2017-07-20 | CODOX M | 02 | N | 240022810 | CLADRIBINE |
| 240008783 | 240005362 | 1.62 | null | null | null | 2015-08-10 | CISPLATIN + ETOPOSIDE | N | null | 240022832 | BEVACIZUMAB |
| 240008784 | 240005362 | null | 50.4 | Curative (C) | 2016-09-16 | 2016-09-16 | CISPLATIN + FLUOROURACIL + RT | N | N | 240022832 | PALBOCICLIB |
| 240008785 | 240005363 | 1.61 | 84 | null | 2017-08-30 | 2017-09-17 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 240022976 | R-EPOCH |
| 240008786 | 240005363 | 1.81 | 75 | null | 2017-04-01 | 2017-04-03 | Cytarabine HD + Methotrexate HD | null | N | 240022976 | CYTARABINE |
| 240008787 | 240005364 | 1.62 | 72.9 | Palliative (P) | 2015-07-29 | 2015-08-31 | LENALIDOMIDE | N | null | 240023081 | AML17 TRIAL |
| 240008790 | 240005366 | 1.65 | 59.8 | Adjuvant (A) | 2017-05-10 | 2017-05-10 | CISPLATIN + FLUOROURACIL | Y | N | 240023188 | DOXORUBICIN |
| 240008791 | 240005367 | 1.76 | 86 | Curative (C) | 2017-12-18 | 2017-12-19 | CHOP R + METHOTREXATE | N | null | 240023200 | GDP |
| 240008792 | 240005368 | 1.65 | 69.9 | Palliative (P) | 2014-11-12 | 2016-05-08 | Cyclophosphamide oral | N | N | 240023221 | CISPLATIN + FLUOROURACIL |
| 240008793 | 240005369 | 1.72 | 85.5 | Curative (C) | 2017-08-11 | 2017-08-13 | AML 19 TRIAL | 01 | N | 240023235 | FCR |
| 240008794 | 240005369 | null | 90.9 | Adjuvant (A) | 2014-03-09 | 2014-08-03 | Docetaxel + Gemcitabine with GCSF | N | N | 240023235 | CISPLATIN + TOPOTECAN |
| 240008795 | 240005369 | 1.5 | 60 | Adjuvant (A) | 2018-05-19 | 2018-06-19 | Cyclophosphamide + Vincristine | 02 | N | 240023235 | CISPLATIN + TOPOTECAN |
| 240008796 | 240005370 | 1.8 | 53.3 | Palliative (P) | 2015-12-11 | 2015-12-12 | RUXOLITINIB | 02 | N | 240023311 | CISPLATIN + ETOPOSIDE + RT |
| 240008797 | 240005371 | 1.78 | 67.7 | Palliative (P) | 2013-11-19 | 2013-12-09 | AML17 TRIAL | N | N | 240023314 | CETUXIMAB |
| 240008798 | 240005372 | 1.64 | 88 | Disease modification (D) | 2014-10-23 | 2014-10-26 | CHOEP - 21 days | N | N | 240023318 | BEVACIZUMAB |
| 240008799 | 240005372 | 1.6 | 70.2 | Palliative (P) | 2014-07-14 | 2014-08-03 | ABVD | 02 | N | 240023318 | AML17 TRIAL |
| 240008800 | 240005373 | 1.53 | null | Palliative (P) | 2015-05-02 | 2015-05-04 | Cisplatin + Topotecan | Y | N | 240023629 | CISPLATIN + FLUOROURACIL |
| 240008801 | 240005373 | null | 86.1 | null | 2016-08-08 | 2016-08-25 | Methotrexate intrathecal | N | null | 240023629 | TRIPLE INTRATHECAL |
| 240008802 | 240005373 | 1.3 | null | Curative (C) | 2016-07-18 | 2016-08-09 | Vincristine (weekly) | N | null | 240023629 | LEAM |
| 240008803 | 240005374 | null | 74 | Curative (C) | 2015-08-24 | 2015-08-27 | R CODOX M | N | N | 240023672 | CYTARABINE |
| 240008804 | 240010954 | 1.47 | 69.4 | Curative (C) | 2013-10-01 | 2013-10-01 | INCA TRIAL | N | null | 240023675 | CISPLATIN + ETOPOSIDE |
| 240008805 | 240010954 | 1.59 | 74.2 | Adjuvant (A) | null | 2018-04-20 | AML17 TRIAL | N | N | 240023675 | ABVD |
| 240008806 | 240005375 | 1.59 | null | null | null | 2017-11-15 | BEVACIZUMAB + CARBO + DOCETAXEL | N | N | 240023687 | R-EPOCH |
| 240008807 | 240005375 | 1.81 | null | Not known (9) | 2016-07-12 | 2016-07-21 | MPV (cycle 1-4) | 2 | N | 240023687 | CAPECITABINE + RT |
| 240008808 | 240005376 | 1.62 | 70.4 | Disease modification (D) | null | 2016-11-26 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 240023715 | PALBOCICLIB |
| 240008809 | 240005377 | 1.55 | 58.2 | Palliative (P) | 2017-02-17 | 2017-03-11 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 240023721 | AML18 TRIAL |
| 240008810 | 240005377 | 1.59 | 76.4 | Adjuvant (A) | 2018-01-06 | 2018-01-13 | Cytarabine Low Dose | N | N | 240023721 | CISPLATIN + PACLITAXEL |
| 240008811 | 240005377 | 1.75 | 0 | Curative (C) | 2014-09-15 | 2014-09-17 | Cyclophosphamide TBI Allograft | Y | N | 240023721 | ABVD |
| 240008812 | 240005378 | 1.56 | 53 | Curative (C) | 2014-04-19 | 2014-04-22 | Cyclophosphamide oral | Y | N | 240023752 | R-EPOCH |
| 240008813 | 240005378 | 1.55 | 0 | Curative (C) | 2016-04-13 | 2016-04-13 | Capecitabine + Oxaliplatin 14day | 02 | N | 240023752 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE + RITUXIMAB |
| 240008814 | 240005379 | 1.83 | 75.6 | null | 2018-01-25 | 2018-02-08 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | null | N | 240023771 | RAVVA TRIAL |
| 240008815 | 240005380 | 1.62 | 63.9 | Curative (C) | 2016-06-13 | 2016-07-14 | Cisplatin + Topotecan | N | N | 240023832 | CYTARABINE INTRATHECAL |
| 240008816 | 240005380 | 1.55 | 77 | Palliative (P) | 2018-07-04 | 2018-08-04 | GemCarbo Days 1+8 | 2 | null | 240023832 | CISPLATIN + TOPOTECAN |
| 240008817 | 240005381 | 1.53 | 86 | Adjuvant (A) | 2014-09-18 | 2014-09-18 | Methotrexate intrathecal | Y | Y | 240023933 | DOXORUBICIN |
| 240008818 | 240010959 | 1.74 | 32.8 | Radical (R) | 2015-03-30 | 2015-04-05 | CODOX M | null | N | 240023957 | IBRUTINIB |
| 240008819 | 240010959 | 1.5 | 84 | Radical (R) | 2016-01-15 | 2016-01-15 | Cisplatin + Vinorelbine (IV) | null | N | 240023957 | ABVD |
| 240008820 | 240005382 | null | 61 | null | 2014-08-23 | 2014-09-05 | RCEOP | 02 | null | 240024043 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 240008821 | 240005383 | 1.67 | 80 | Disease modification (D) | 2017-01-15 | 2017-01-20 | Oxaliplatin + Modified de Gramont | 02 | N | 240024118 | ABVD |
| 240008822 | 240005384 | 0 | 81.9 | Palliative (P) | 2015-04-13 | 2015-04-14 | IBRUTINIB | 02 | N | 240024254 | R CODOX M |
| 240008823 | 240005385 | 1.68 | 54 | Disease modification (D) | 2015-08-19 | 2015-08-21 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 02 | N | 240024466 | ABVD |
| 240008824 | 240005386 | null | 80.8 | Palliative (P) | 2018-08-05 | 2018-08-15 | Cisplatin + Topotecan | 2 | N | 240024547 | PACLITAXEL |